Semaglutide Extends Mice Lifespan by 12% Beyond Calorie Restriction

Key points

• Researchers from UC Berkeley and the University of Copenhagen treated 20-month-old female mice with semaglutide, finding a median lifespan increase of 92 days (12.4%) compared to controls.
• The drug improved physical and cognitive functions, including grip strength, spatial memory, and blood sugar regulation, while reducing chronic inflammation and cellular aging.
• Compared to a calorie-restricted group, semaglutide-treated mice showed additional benefits in exploratory behavior and memory, suggesting mechanisms beyond weight loss.
• The findings apply only to inbred female mice; no human clinical trials have yet confirmed these anti-aging effects in healthy elderly populations.

Background

This follows earlier 2026 studies on GLP-1 drugs like semaglutide and experimental compounds like TOFA, which explored weight loss mechanisms and potential metabolic benefits in mice. Previous research indicated that GLP-1 drugs may influence fat mobilization and appetite suppression, but this study focuses on lifespan extension and aging markers in older subjects.

How outlets are covering it

Nature and Chosun Ilbo emphasize the direct lifespan extension and improved physiological/cognitive markers in mice, highlighting the drug's potential beyond weight loss. The i Paper notes the 12% lifespan increase but cautions that results from small animals may not translate to humans, citing historical limitations in calorie restriction studies. All sources agree that human trials are needed to confirm these findings.

Why it matters

If confirmed in humans, semaglutide could shift from a weight-loss and diabetes treatment to a potential anti-aging therapy, impacting millions of users and healthcare policies. However, the current evidence is limited to mice, and human applicability remains uncertain.

What to watch

Researchers call for long-term clinical trials to determine if semaglutide alters human aging processes or lifespan. Further studies will need to assess safety, dosing, and long-term effects in diverse human populations.